Objective: Cancer arises as a result of the failure of the mechanisms controlling normal division in a group of cells. It is known that some new synthesis compounds intended for use in cancer treatment have anti-fungal, anti-bacterial, anti-carcinogenic effects. In this study, it was aimed to apply the newly synthesized B-108 compound to the A-549 cell line and then to investigate the effect of this compound on the ERCC1 gene expression profile.
Materials and Methods: Firstly, compound B-108 was synthesized in our study. Afterwards, this synthesized molecule was applied in eight different concentrations (1-100 μg/ml) in A-549 cell line and 3-(4,5-dimethylthiazol-2-yl)-2,5-yl for 24 hours, 48 hours and 72 hours. Anticancer activities were determined using diphenyltetrazolium bromide (MTT) method. Expression level of DNA repair gene (ERCC1) was determined using RT-PCR method.
Results: As a result, it was determined that the molecule applied to the A-549 cell line showed the highest activity after 72 hours of incubation. It was observed that the ERCC1 gene expression of the molecule applied on lung cancer was lower than the control group.
Discussion: Considering the current study results, low expression of ERCC1 shows that compound B-108 correlates with overall survival on lung cancer cells.
Birincil Dil | İngilizce |
---|---|
Konular | Sağlık Kurumları Yönetimi |
Bölüm | Temel Tıp Bilimleri Araştırma Yazıları |
Yazarlar | |
Yayımlanma Tarihi | 31 Aralık 2022 |
Kabul Tarihi | 19 Aralık 2022 |
Yayımlandığı Sayı | Yıl 2022Cilt: 44 Sayı: 4 |